Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELESTIAL trial of cabozantinib versus placebo in previously treated advanced hepatocellular carcinoma
NL-OMON23693Unknown
- Sponsor
- Exelixis, Inc.
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Cabozantinib with Placebo (2 arms). Primary endpoint: Overall survival. Status: unknown.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON23693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23693.